根據最新的財務報表(Form-10K),Aspira Women's Health Inc 的總資產為 $5,淨損失為 $-13
AWHL 的關鍵財務比率是什麼?
Aspira Women's Health Inc 的流動比率為 0.62,淨利潤率為 -144.44,每股銷售為 $0.63。
Aspira Women's Health Inc 的收入按細分市場或地理位置如何劃分?
Aspira Women's Health Inc 最大收入來源為 Bio-analytic and Diagnostic Services,在最近的收益報告中收入為 9,154,000。就地區而言,United States 是 Aspira Women's Health Inc 的主要市場,收入為 9,154,000。
Aspira Women's Health Inc 是否盈利?
無,根據最新的財務報表,Aspira Women's Health Inc 的淨損失為 $-13
Aspira Women's Health Inc 有負債嗎?
是的,Aspira Women's Health Inc 的負債為 8
Aspira Women's Health Inc 的流通股有多少?
Aspira Women's Health Inc 的總流通股為 17.4
關鍵數據
前收市價
$0.32
開盤價
$0.3451
當日範圍
$0.28 - $0.36
52週區間
$0.02 - $0.71
交易量
28.5K
平均成交量
62.7K
股息收益率
--
每股盈餘 (TTM)
-0.99
市值
$17.2M
什麼是 AWHL?
Aspira Women's Health, Inc. engages in the provision of bio-analytic and diagnostic services. The company is headquartered in Austin, Texas and currently employs 66 full-time employees. The company went IPO on 2000-09-29. The firm's portfolio includes OvaWatch and the Ova1Plus workflow, offered to clinicians as OvaSuite. OvaWatch is used to assess ovarian cancer risk for women with an adnexal mass where their initial clinical assessment indicates the mass is indeterminate or benign. The Ova1Plus is a reflex process of two tests, Ova1 and Overa, to assess the risk of ovarian malignancy in women with an adnexal mass planned for surgery. Its product pipelines are OVAinform and ENDOinform. OVAinform is a test that combines serum proteins, clinical data (metadata), and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass. ENDOinform is a test program that combines serum proteins, clinical data (metadata), and miRNA for the identification of endometriosis.